February 28, 2011
Life value
STELLAPHARM was born to care and protect patient’s health, to help enhancing their lives and living longer. Your health, for today and for future.
In cooperation with our exclusive distributor – Khuong Duy Pharmaceutical Co., Ltd, on 28 February 2011, STADA – VN JOINT VENTURE CO., LTD held a New Year Meeting for all KD’s Chief of Representative Office and provincial agents (distributors).

During the meeting, attendants discussed the difficulties faced in their operations last year and proposed solutions. Another topics of discussion were goals for 2011 and plans for future development.
STELLAPHARM is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, anti-viral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.
The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.
Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An Town, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: info@stellapharm.com | W: www.stellapharm.com
Thành phố Hồ Chí Minh và Geneva, ngày 10 tháng 9 năm 2026 – Stellapharm và Medicines Patent Pool (MPP) ký Thỏa thuận cấp phép (Sublicence Agreement) về việc phát triển, sản xuất và cung ứng thuốc generic chứa hoạt chất baloxavir marboxil do Roche nắm sở hữu bản quyền. Đây là thuốc kháng virus
Ho Chi Minh City and Geneva, 10 September 2026 – Stellapharm and Medicines Patent Pool (MPP) signed a sublicence agreement to develop, manufacture and supply a generic version of Roche’s baloxavir marboxil, a single-dose antiviral treatment recommended by the World Health Organization (WHO) for influenza. The agreement will allow Stellapharm to manufacture and supply baloxavir